Sutinen Pinja, Hecht Idan, Karesvuo Minna, Jeon Sohee, Karesvuo Petteri, Tuuminen Raimo
Helsinki Retina Research Group, University of Helsinki, Helsinki, Finland.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Acta Ophthalmol. 2025 Jun;103(4):416-422. doi: 10.1111/aos.17430. Epub 2024 Dec 20.
Here we examine the association of anti-inflammatory therapy with anatomical and functional outcomes of epiretinal membrane surgery.
The study included consecutive patients having gone through epiretinal membrane surgery at Helsinki University Hospital, Finland, between 2017 and 2021. The association of perioperative intravitreal and postoperative topical anti-inflammatory therapies with surgical outcomes was assessed.
In total, 214 eyes of 214 patients with a mean age of 71.2 ± 8.2 years were studied. At 1-month, perioperative intravitreal use of triamcinolone acetonide (n = 27) was associated with a significant proportional and absolute improvement in foveal thickness (-15.9 ± 18.4% vs. -4.2 ± 25.6%, p = 0.003 and -86.2 ± 109.6 μm vs. -33.7 ± 94.3 μm, p = 0.004), and central subfield macular thickness (-14.7 ± 16.5% vs. -6.3 ± 16.9%, p = 0.009 and -80.6 ± 102.8 μm vs. -36.1 ± 75.9 μm, p = 0.004) when compared to those without triamcinolone acetonide. Furthermore, best-corrected visual acuity (BCVA) gain showed a non-significant yet corresponding trend favouring intraoperative intravitreal use of triamcinolone acetonide (0.21 ± 0.27 vs. 0.09 ± 0.28 LogMAR units, p = 0.062). Postoperative use of topical non-steroidal anti-inflammatory drugs (NSAIDs) (n = 36) as adjunct therapy showed no significant advantage in anatomical outcomes or BCVA gain when compared to those without NSAIDs (all p > 0.05). Triamcinolone acetonide remained significant for proportional and absolute improvement in foveal thickness (p = 0.019 and p = 0.006) and in central subfield macular thickness (p = 0.013 and p = 0.006) when controlled for confounding factors patient age and gender and topical NSAID use.
Intraoperative intravitreal use of triamcinolone acetonide improved short-term anatomical outcomes in patients who underwent epiretinal membrane surgery.
在此我们研究抗炎治疗与视网膜前膜手术的解剖学和功能结局之间的关联。
该研究纳入了2017年至2021年间在芬兰赫尔辛基大学医院接受视网膜前膜手术的连续患者。评估了围手术期玻璃体内注射和术后局部抗炎治疗与手术结局的关联。
总共研究了214例患者的214只眼睛,平均年龄为71.2±8.2岁。在术后1个月时,与未使用曲安奈德的患者相比,围手术期玻璃体内使用曲安奈德(n = 27)与黄斑中心凹厚度的显著比例和绝对值改善相关(-15.9±18.4%对-4.2±25.6%,p = 0.003;-86.2±109.6μm对-33.7±94.3μm,p = 0.004),以及黄斑中心子区域厚度的改善(-14.7±16.5%对-6.3±16.9%,p = 0.009;-80.6±102.8μm对-36.1±75.9μm,p = 0.004)。此外,最佳矫正视力(BCVA)的提高显示出有利于术中玻璃体内使用曲安奈德的非显著但相应趋势(0.21±0.27对0.09±0.28 LogMAR单位,p = 0.062)。与未使用非甾体抗炎药(NSAIDs)的患者相比,术后使用局部NSAIDs(n = 36)作为辅助治疗在解剖学结局或BCVA提高方面没有显著优势(所有p>0.05)。在控制了患者年龄、性别和局部NSAIDs使用等混杂因素后,曲安奈德在黄斑中心凹厚度(p = 0.019和p = 0.006)和黄斑中心子区域厚度(p = 0.013和p = 0.006)的比例和绝对值改善方面仍然具有显著意义。
术中玻璃体内使用曲安奈德可改善接受视网膜前膜手术患者的短期解剖学结局。